Benign Brain Tumors, Proton Therapy
Conditions
Keywords
MRI
Brief summary
The main objective is to detect with TESLA multiparametric 3 MRI, the MRI secondary changes to protontherapy irradiation and to correlate them with TEL mapping, physical dose and biological dose. A model should thus be able to be proposed at the end of the study.
Interventions
DEVICEMRI 3 tesla
1.5 Tesla MRIs, usually used as pre-treatment and, between 3 and 6 months after irradiation, are replaced in the study by 3 Tesla MRIs (pre-treatment and at 6 months) In addition, two additional MRIs, also performed with a 3 Tesla magnetic field, will be performed: * During treatment when half of the prescribed dose has been delivered. * 1 month after the end of the irradiation.
Sponsors
Centre Francois Baclesse
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically proven or highly probable grade I meningiomas, histologically proven grade II meningiomas. * Only meningiomas of the anterior and middle floors of the base of the skull are included. * Indication of proton therapy retained in RCP and / or proton therapy technical staff (Caen site) * Patient aged 18 or over * Patient affiliated to a social security scheme * Signature of informed consent before any specific procedure related to the study
Exclusion criteria
* History of brain or face irradiation. * Implant or foreign body that can alter MRI imaging. * Contraindication to MRI (pace maker, claustrophobia ...) - Hypersensitivity to gadoteric acid, to meglumine or to any medicine containing gadolinium * Genetic radio sensitizing syndrome * Known neurological comorbidities (stroke, Parkinson's, etc.) that may impact MRI data. * Simultaneous participation in a therapeutic clinical trial * Patient unable to undergo the trial follow-up for geographic, social or psychopathological reasons * Pregnant or breastfeeding women * Persons deprived of their liberty (see article L 1121-6 CSP), * Adults who are the subject of a legal protection measure or unable to express their consent (see article L 1121-8)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate by TESLA multiparametric 3 MRI the modifications of the MRI signal :Change from Baseline at 1, 3 and 6 months | Up to 6 months | modifications of the MRI signal on the various sequences carried out, during the study |
Countries
France
Outcome results
None listed